

CrossMark

# A retrospective multi-institutional study of treatment for mild gestational diabetes in Japan

Takashi Sugiyama <sup>a,1,\*</sup>, Hirohito Metoki <sup>a</sup>, Hirotaka Hamada <sup>a</sup>, Hidekazu Nishigori <sup>a</sup>, Masatoshi Saito <sup>a</sup>, Nobuo Yaegashi <sup>a</sup>, Hideto Kusaka <sup>b,1</sup>, Reo Kawano <sup>c</sup>, Kiyoshi Ichihara <sup>c</sup>, Ichiro Yasuhi <sup>d</sup>, Yuji Hiramatsu <sup>e</sup>, Norimasa Sagawa <sup>f</sup> The Japan Gestational Diabetes Study Group<sup>2</sup>

<sup>a</sup> Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8574, Japan

<sup>b</sup> Department of Obstetrics and Gynecology, National Hospital Organization Mie Chuo Medical Center, Tsu, Mie 514-1101, Japan

<sup>c</sup> Department of Laboratory Science, Faculty of Health Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan

<sup>d</sup> Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Omura, Nagasaki 856-8562, Japan

<sup>e</sup> Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

<sup>f</sup> Department of Obstetrics and Gynecology, Rakuwakai Otowa Hospital, Kyoto 607-8062 Japan

\* Corresponding author at: Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai City, Miyagi 980-8574, Japan. Tel.: +81 22 717 7254; fax: +81 22 717 7258.

http://dx.doi.org/10.1016/j.diabres.2013.12.017

E-mail address: tmyka9922@gmail.com (T. Sugiyama).

<sup>&</sup>lt;sup>1</sup> These authors contributed equally to this work.

<sup>&</sup>lt;sup>2</sup> The contributors of the Japan Gestational Diabetes Study Group are shown as follows: Hokkaido University – Hisanori Minakami, Mamoru Morikawa; Saitama Medical University – Atsushi Itakura, Yoshinori Mizukami; Nishisaitama-Chuo National Hospital – Atsushi Yoshida; Gunma University Schoo of Medicine – Koushi Hashimoto, Aya Ohsaki; Saiseikai Central Hospital – Sonoko Anazawa, Kiyoshi Kamei; Aiiku Hospital – Masao Nakabayashi, Yoshiji Takeda; Keio University – Kei Miyakoshi, Satoru Ikenoue; Shiseikai Daini Hospital – Masashi Honda; National Hospital Organization Nagasaki Medical Center – Haruhiko Sago, Naoko Arata, Kohei Ogawa; Nihon University School of Medicine - Tatsuo Yamamoto, Masashi Nagaishi; Tokyo Medical Center - Jun Takahashi; Tokyo Women's University School of Medicine - Yoshio Matsuda, Yasuo Makino, Masaki Ogawa, Mayumi Sanaka; Tokyo Women's University Yachiyo Medical Center – Naoki Masaoka, Yoshiyuki Nakajima; St. Marianna University School of Medicine – Mamoru Tanaka, Suguru Igarashi; Yokohama City University Medical Center – Tsuneo Takahashi, Mika Okuda; Ebina Hospital: Yasue Omori, Natsuko Suzuki; Mie University Graduate School of Medicine – Tomoaki Ikeda, Yuki Kamimoto; Osaka City General Hospital – Mariko Fukumoto Masayuki Hosoi; Nara Medical University – Hiroshi Kobayashi, Katsuhiko Naruse; Osaka Medical Center and Research Institute for Maternal and Children Health – Nobuaki Mitsuda, Keisuke Ishii, Masako Waguri, Isao Nakanishi; Okayama University School of Medicine – Hisashi Masuyama, Etsuko Nobumoto; The Sakakibara Heart Institute of Okayama – Ikki Simizu; National Hospital Organization Kokura Medical Center – Naoko Suwaki; Tokushima University School of Medicine – Minoru Irahara, Kazutoshi Maeda; Ehime Prefectural Central Hospital – Emiko Abe; Kurume Medical University – Daizo Hori, Yutaka Kozuma; National Hospital Organization Nagasaki Medical Center – Ichiro Yasuhi, Hiroshi Yamashita; Nagasaki University School of Medicine – Eiji Kawasaki, Ai Sakanaka; Miyazaki University School of Medicine – Hiroshi Sameshima, Yuki Kodama; Uenomachi Kajiya Clinic – Masako Kajiya; Kagoshima City Hospital – Masato Kamitomo. 0168-8227/\$ – see front matter © 2013 Elsevier Ireland Ltd. All rights reserved.

#### ARTICLE INFO

Article history: Received 9 April 2013 Received in revised form 17 October 2013 Accepted 18 December 2013 Available online 15 January 2014

### Keywords:

Gestational diabetes mellitus (GDM) Treatment Pregnancy outcome LGA

#### ABSTRACT

Aims: To determine whether treating mild gestational diabetes mellitus (GDM) is associated with improvement of pregnancy outcomes in Japan.

Methods: In a multi-institutional retrospective study, we examined pregnant women meeting the criteria for mild GDM (i.e., only one abnormal value [OAV] for 75-g OGTT; fasting glucose  $\geq$ 100 mg/dL, 1-h postprandial glucose  $\geq$ 180 mg/dL, and 2-h postprandial glucose  $\geq$ 150 mg/dL), receiving either routine prenatal care (non-treatment group) or dietary intervention alone or dietary intervention with self-monitoring of blood glucose and/or insulin therapy, if necessary (treatment group). Pregnancy outcomes were compared between these groups.

Results: Data from 893 eligible women were collected from 30 institutions. Participants included 542 untreated and 351 treated women. Although there were no significant differences in baseline clinical characteristics or maternal and perinatal outcomes between these groups, the incidence of large-for-gestational-age (LGA) infants was lower in the treatment group (P = 0.07). Multiple logistic regression analysis (MLRA) revealed that pre-pregnancy BMI and gestational weight gain were associated with LGA infants, while 75-g OGTT results were unrelated to LGA. When overweight and obese women were the subjects, the number of LGA infants was significantly lower in the intervention than in the control group, and gestational weight gain was significantly lower in the treatment than in the control group. MLRA showed that intervention was significantly related to a lower incidence of LGA infants.

Conclusions: Our study suggests that maternal BMI impacts fetal growth and that treatment for overweight or obese mothers with OAV is associated with a lower frequency of LGA infants.

© 2013 Elsevier Ireland Ltd. All rights reserved.

# 1. Introduction

Gestational diabetes mellitus (GDM) is defined as glucose intolerance that first occurs or is first identified during pregnancy [1]. New criteria for diagnosing GDM were recently proposed by the International Association of Diabetes in Pregnancy Study Group (IADPSG) [2]. Maternal hyperglycemia correlates with adverse maternal, fetal, and/or neonatal outcomes [3]. The new criteria are based primarily on glucose levels associated with a 1.75-fold increased risk of giving birth to a large-for-gestational-age (LGA) infant in the Hyperglycemia Adverse Pregnancy Outcome (HAPO) study [3]. The frequency of this condition is increasing worldwide. In fact, the new criteria will result in a GDM prevalence of 17.8% [2], doubling the numbers of pregnant women currently diagnosed. LGA infants are well known to be a significant obstetrical complication of GDM [4,5]. The neonatal complications of GDM, including hypoglycemia and hypocalcemia, are due mainly to fetal hyperinsulinemia, which results from maternal hyperglycemia. The long-term complications of GDM are type 2 diabetes development in the mother [6,7] and diabetes and/or obesity in their offspring [8,9].

In 2010, the criteria for diagnosing GDM proposed by the IADPSG were adopted in Japan. The frequency of GDM consequently increased 2–4-fold as compared with the previous criteria [10], i.e., meeting at least two of three threshold values from a 75-g oral glucose tolerance test (OGTT); fasting glucose  $\geq$ 100 mg/dL, 1-h postprandial glucose  $\geq$ 180 mg/dL, and 2-h postprandial glucose  $\geq$ 150 mg/dL, as

proposed by the Japan Society of Obstetrics and Gynecology (JSOG) [11]. These criteria are similar to those proposed by the IADPSG (meeting at least two of three threshold values from a 75-g OGTT; fasting plasma glucose  $\geq$ 92 mg/dL, 1-h plasma glucose  $\geq$ 180 mg/dL, and 2-h plasma glucose  $\geq$ 153 mg/dL) [10] and the American Diabetes Association (meeting at least two of three threshold values from a 75-g OGTT; fasting plasma glucose  $\geq$ 95 mg/dL, 1-h plasma glucose  $\geq$ 95 mg/dL, 1-h plasma glucose  $\geq$ 180 mg/dL, and 2-h plasma glucose  $\geq$ 95 mg/dL, 1-h plasma glucose  $\geq$ 180 mg/dL, and 2-h plasma glucose  $\geq$ 155 mg/dL) [12]. Among women with newly diagnosed GDM, most had only one abnormal value (OAV) based on the JSOG criteria [our unpublished data, under submission]. A multi-institutional retrospective review was thus performed by the Japan GDM Study Group (JGSG) to assess whether the treatment of mild GDM, i.e., one abnormal OGTT value, improves pregnancy outcomes in Japan.

## 2. Materials and methods

## 2.1. Study design

The present retrospective study was conducted in 30 general hospitals in Japan from 2005 to 2010. The protocol was approved by the ethics committee at each of the 30 collaborating centers. All women with a singleton pregnancy and no prior diagnosis of diabetes mellitus were included. Women with multi-fetal gestations, pre-gestational diabetes, previous treatment for gestational diabetes or an active chronic systemic disease other than chronic hypertension, and those with the second of two pregnancies in the same year Download English Version:

https://daneshyari.com/en/article/5899388

Download Persian Version:

https://daneshyari.com/article/5899388

Daneshyari.com